BNP Paribas Financial Markets Has $27.15 Million Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

BNP Paribas Financial Markets grew its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 432.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 850,823 shares of the company's stock after purchasing an additional 691,123 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.68% of Apellis Pharmaceuticals worth $27,150,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Teacher Retirement System of Texas boosted its holdings in Apellis Pharmaceuticals by 9.4% during the fourth quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company's stock worth $691,000 after buying an additional 1,864 shares during the last quarter. KBC Group NV raised its position in shares of Apellis Pharmaceuticals by 3,862.3% in the 4th quarter. KBC Group NV now owns 104,287 shares of the company's stock valued at $3,328,000 after acquiring an additional 101,655 shares during the period. Entropy Technologies LP bought a new position in Apellis Pharmaceuticals during the 4th quarter worth approximately $445,000. Barclays PLC grew its holdings in Apellis Pharmaceuticals by 18.0% during the third quarter. Barclays PLC now owns 255,897 shares of the company's stock valued at $7,381,000 after purchasing an additional 39,019 shares during the period. Finally, Merit Financial Group LLC bought a new stake in Apellis Pharmaceuticals in the fourth quarter valued at approximately $254,000. Institutional investors own 96.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on APLS shares. Robert W. Baird decreased their price target on shares of Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Bank of America lowered Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $41.00 to $23.00 in a research report on Friday, May 9th. JPMorgan Chase & Co. boosted their price objective on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. Wedbush dropped their target price on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Finally, Royal Bank of Canada reduced their price target on shares of Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating for the company in a report on Thursday, May 8th. Nine research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $40.42.

Insider Activity at Apellis Pharmaceuticals

In other news, General Counsel David O. Watson sold 5,569 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the sale, the general counsel now directly owns 138,730 shares in the company, valued at approximately $3,482,123. This trade represents a 3.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 6.50% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS traded down $0.58 during mid-day trading on Wednesday, reaching $16.70. The company had a trading volume of 874,648 shares, compared to its average volume of 2,218,541. Apellis Pharmaceuticals, Inc. has a one year low of $16.63 and a one year high of $43.99. The business's 50-day simple moving average is $20.99 and its 200 day simple moving average is $26.99. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -8.23 and a beta of 0.73.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $149.90 million during the quarter, compared to the consensus estimate of $197.61 million. During the same period last year, the business earned ($0.54) earnings per share. The business's revenue was down 3.2% compared to the same quarter last year. On average, research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).